CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Brivaracetam +1 moredrug
Likely dose
Brivaracetam 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03021018
NCT03021018Phase 2Completed
CompareCT.gov

A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

UCB Biopharma S.P.R.L.·interventional·Posted Jan 13, 2017·Updated Dec 16, 2020

In Brief

A Phase 2 clinical trial evaluating Brivaracetam and Lorazepam for Epilepsy. Completed, enrolled 46 participants across 14 sites.

Detailed Summary

The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 13, 2017
Enrollment StartFeb 6, 2017
Primary CompletionApr 27, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.5 years ago

Interventions

Brivaracetamdrug

* Pharmaceutical Form: Solution for infusion * Concentration: 10 mg/ml * Route of Administration: intravenous

Lorazepamdrug

* Pharmaceutical Form: Solution for injection * Route of Administration: intravenous